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Maladaptive plasticity can be defined as behavioral loss or even development of disease
symptoms resulting from aberrant plasticity changes in the human brain. Hyperkinetic
movement disorders, in the neurological or psychiatric realms, have been associated with
maladaptive neural plasticity that can be expressed by functional changes such as an
increase in transmitter release, receptor regulation, and synaptic plasticity or anatomical
modifications such as axonal regeneration, sprouting, synaptogenesis, and neurogenesis.
Recent evidence from human and animal models provided support to the hypothesis that
these phenomena likely depend on altered dopamine turnover induced by long-term drug
treatment. However, it is still unclear how and where these altered mechanisms of corti-
cal plasticity may be localized. This study provides an up-to-date overview of these issues
together with some reflections on future studies in the field, particularly focusing on two
specific disorders (levodopa-induced dyskinesias in Parkinson’s disease patients and tar-
dive dyskinesias in schizophrenic patients) where the modern neuroimaging approaches
have recently provided new fundamental insights.
Keywords: levodopa-induced dyskinesias, tardive dyskinesias, hyperkinetic movement disorders, inferior frontal
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INTRODUCTION
Plasticity refers to the ability of the nervous system to change the
effectiveness of transmission in neural circuits. This can involve
changes at several levels (neuronal, synaptic, protein, or genomic
structure) and modulates both the structure and function of neu-
ronal networks. Several human and animal studies demonstrated
that exercise and/or behavioral enrichment can increase neuronal
survival and resistance to brain insult, promote brain vasculariza-
tion, stimulate neurogenesis, and enhance learning [for review, see
Ref. (1)].
Although neural plasticity is generally viewed as an adaptive
process, there is considerable evidence that plasticity can also
be maladaptive [for review, see Ref. (2)]. For instance, sensory
deprivation, chronic stress, and excessive exercise would reduce
variability and impair adaptability. In particular, chronic stress
is associated with a loss of neurons and synapses. Furthermore,
stress may increase activity in certain brain regions, such as the
amygdala and the mesolimbic dopaminergic system, leading to
hypertrophy of these structures (3). Again, Byl et al. (4) showed
that monkeys that were over-trained to make a particular highly
specific hand movement sometimes developed difficulties in mov-
ing their hands in a similar manner to focal hand dystonia. The
somatosensory cortex of these animals was less organized than that
of healthy monkeys, with larger receptive fields and overlapping
representations of the individual digits. A change in the pattern
of connectivity in the sensory and motor cortices was thought
to lead to inappropriate associations between inputs and outputs
of the motor areas and cause errors in selecting muscles used in
voluntary movement.
However, maladaptive neural plasticity may be triggered not
only by exercise and/or behavioral deprivation, but also by other
factors, such as chronic drug therapy. In the last few years, several
influential authors (5–7) proposed that some hyperkinetic move-
ment disorders [levodopa-induced dyskinesias (LIDs), primary
dystonia, Huntington’s disease, and tardive dyskinesias (TDs)] are
caused by maladaptive synaptic plasticity. The scope of this study
is to summarize evidence on the role of dopaminergic replacement
in inducing maladaptive neural changes in these hyperkinetic dis-
orders, delineating the presence of shared neural mechanisms.
Particular attention will be paid to recent evidence coming from
molecular and neuroimaging studies that allow in vivo evaluation
of neural plasticity.
PARKINSON’S DISEASE WITH LEVODOPA-INDUCED
DYSKINESIAS
The classical clinical picture of Parkinson’s disease (PD) consists
of motor deficits, such as akinesia, rigidity, tremor, and postural
dysfunction. These motor symptoms are greatly improved by
treatments with dopamine (DA) replacement therapy or DA ago-
nists, but after 4–6 years, the therapeutic window becomes narrow
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and patients start to experience very disabling motor symptoms,
such as motor fluctuations and LIDs. LIDs in PD has been thought
to originate from an imbalance between “direct” and “indirect”
pathways regulating neural activity in the striato-frontal network
(8, 9). The neurons of the direct pathway project to the globus
pallidus pars interna (GPi) and onward to the thalamus. The neu-
rons comprise the indirect pathway project to the globus pallidus
pars externa (GPe), where they synapse with more GABAergic
projection neurons. In turn, these neurons project to the sub-
thalamic nuclei (STN) and form synapses with the glutamatergic
neurons that provide output to the GPi and the substantia nigra
pars reticulata (SNr). The essential pathophysiological character-
istic of the LIDs state is the presence of under-activity of the
indirect pathway and overactivity of the direct pathway. In the
last few years, this model has been reinforced and modified to
extend knowledge about the interplay between striatal nuclei and
the frontal cortex. Indeed, LIDs have also been demonstrated
to be associated with a sequence of events that includes pre-
synaptic (i.e., increased synaptic level of DA) and post-synaptic
modifications (i.e., downstream changes in proteins and genes),
and abnormalities in non-DA transmitter systems (9). Overall,
all these events combine to produce alterations in the firing pat-
terns and the coherence between the basal ganglia and the cor-
tex, leading to excessive disinhibition of thalamocortical neurons
and overactivation of frontal areas, with specific involvement of
motor, premotor, and prefrontal cortices (10, 11). The presence of
altered cortical excitability in the motor and prefrontal cortex has
also been demonstrated by electrophysiological studies employ-
ing transcranial magnetic stimulation (TMS) in patients with PD
(12, 13). Moreover, as repetitive TMS applied over the supple-
mentary motor area (SMA), the primary motor cortex (M1) was
able to induce a transient reduction of LIDs severity (14, 15).
Despite the traditional striato-thalamo-cortical pathways, in the
last few years, advances in the neurophysiological field provide
alternative scenarios highlighting the involvement of other circuits
involved in the pathophysiological mechanisms of LIDs. In par-
ticular, reduction of peak-dose dyskinesia for up to 4 weeks was
described following repeated sessions of continuous theta burst
stimulation (cTBS) delivered bilaterally to the lateral cerebellum
(16). This later finding would seem to support the hypothesis that
alterations in cerebellar sensory processing function, occurring
secondary to abnormal basal ganglia signals reaching it, may be
an important element contributing to the maladaptive sensori-
motor plasticity of motor cortex and the emergence of abnormal
involuntary movements (17).
TARDIVE DYSKINESIAS IN PSYCHIATRIC DISORDERS
Chronic blockage of DA receptors by anti-psychotic drugs in
patients with psychiatric disorders has been known to produce
another well-known hyperkinetic movement disorder named TDs.
Originally, the term TDs referred to abnormal movements pro-
duced by long-term DA receptor antagonist therapy, mainly
characterized by rapid, repetitive, stereotypic movements affect-
ing mainly the oral, buccal, and lingual areas, and less move-
ments affecting the limb and the trunk; however, other phe-
nomenologies have been described in TDs, such as dystonia and
akathisia (18). More than half of TDs cases may persist, even after
conventional antipyschotics are switched to atypical ones (19), or
anti-psychotics are discontinued (20). The most popular patho-
physiological model for TD is based on DA receptor hypersensitiv-
ity triggered by anti-psychotic drugs (7, 21, 22). According to this
theory, chronic use of DA antagonists, particularly at high levels
of antagonism (i.e., haloperidol), results in gradual hypersensiti-
zation of DA receptors. Indeed, chronic administration of neu-
roleptics might cause adaptive changes in DA receptors, causing
an increase in the number of D2 receptors (23). D2 receptors being
expressed on indirect pathway medium-spiny neurons and being
inhibitory, the consequence of D2 hypersensitivity might deter-
mine disinhibition of the GPi and the subthalamic nucleus (7).
Support for hypersensitivity of DA receptors in TDs mainly comes
from rodent models (24). Moreover, further support comes from
clinical observations that increasing anti-psychotic dosage tem-
porarily suppresses TD (25) whereas withdrawing anti-psychotics
or administering DA agonists exacerbates dyskinetic symptoms
in the short term (21). However, although chronic anti-psychotic
use is associated with D2 hypersensitivity, the evidence support-
ing a direct role on TDs generation are not consistent; indeed, DA
receptors binding in PET studies was not correlated with sever-
ity of dyskinesias and post-mortem studies did not disclose any
difference in number of D2 receptors between patients with and
without TDs (26).
SHARED MALADAPTIVE NEURAL PLASTICITY IN LIDs AND
TDs PATIENTS
Although LIDs and TDs are underlined by drugs acting on the DA
receptor in an opposite way and associated with different diseases,
there is evidence for shared neurodegenerative mechanisms, likely
depending on aberrant neural plasticity in the prefrontal cortex.
The development of LIDs has been attributed in cell studies
to dysfunctional cortico-striatal plasticity triggered by the com-
bined effects of DA denervation and chronic pharmacological DA
replacement (27) and has also been demonstrated in vivo in PD
patients with LIDs (12, 13). Chronic non-physiologic stimulation
of DA receptors on striatal neurons (23) can induce modifica-
tions in NMDA receptors firing and thus the development of
aberrant motor patterns leading to motor complications. This
has provided the rationale for the use of NMDA receptor antag-
onists such as amantadine for treating PD patients with LIDs
(28). Despite the recent evidence on the efficacious effects of
amantadine in ameliorating LIDs [improved motor symptoms in
60–70% of patients; (29)), the restoring of deficient DA with its
precursor l-3,4-dihydroxyphenylalanine (levodopa) is again the
most effective treatment for PD. In the last decades, concern has
been raised that levodopa could have toxic effects on the brain
of patients with PD (30). Although some in vitro studies support
this hypothesis (31), this concern remains uncertain in human
studies (32). Recent evidence coming from neuroimaging stud-
ies has provided new impetus to unravel the potential effects of
levodopa on brain morphometry. Indeed, our group has recently
demonstrated that specific morphological alterations are associ-
ated with the development of LIDs in PD patients (33). Using
unbiased voxel-based morphometry to compare gray matter vol-
ume in dyskinetic and non-dyskinetic patients, closely matched
for age, duration of medication and age of onset, we observed
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significant increases of gray matter volume within the inferior
frontal cortex (IFC), the degree of which increased with the sever-
ity of motor fluctuations. The IFC is an associative area specifically
involved, together with motor and premotor cortices, basal gan-
glia and STN, in the regulation of motor inhibition (34). The
presence of “increased” gray matter volume was in accordance
with other neuroimaging studies investigating the neurobiologi-
cal effects of levodopa treatment in healthy individuals. Indeed,
Salgado-Pineda et al. (35) demonstrated an increased gray matter
volume in healthy controls 1 week after levodopa administration.
All this evidence suggested that levodopa applied in a pulsatile
and non-physiological manner can perturb the normal physiolog-
ical mechanisms that mediate motor control and eventually result
in the remodeling of neuronal contacts and pathways, producing
long-lasting changes and aberrant neural plasticity (i.e., increased
neuronal arborization). The presence of altered anatomy of the
IFC has been confirmed using different populations (36) and neu-
roimaging metrics [i.e., cortical thickness; Ref. (37)] and has raised
an interesting scientific debate on the potential effects of levodopa
on brain morphometry (38, 39). In particular, the main notion
proposed by Vernon and Modo (38) concerned the key role that
animal models of PD would play in providing new insight about
the hypothesis proposed above. Indeed, although several models of
basal ganglia dysfunctions have been proposed to understand the
pathophysiological mechanisms underlying motor manifestations
in patients with PD (8), these changes cannot completely explain
the overall motor symptoms of LIDs in patients. Indeed, a large
body of in vitro and in vivo studies in animal models of parkin-
sonism have suggested an alternative “glutamatergic” hypothesis
for LIDs. Several authors demonstrated that the glutamatergic
cortico-striatal projection to medium-spiny neurons might play an
important role in the priming and development of LIDs, by induc-
tion of abnormal synaptic plasticity at the cortico-striatal level
(40–42). The alteration of glutamatergic transmission as causative
of LIDs has also been demonstrated in vivo by Ahmed et al. (43),
who described abnormalities in glutamate transmission in stri-
atal and frontal regions in dyskinetic compared to non-dyskinetic
patients with PD. Despite the plethora of studies supporting the
glutamatergic contribution to LIDs, there is also a vast consen-
sus that dysfunctions of the serotonergic system are implicated
in the development of LIDs and other complications of levodopa
therapy. Indeed, serotonin neurons have the ability to synthesize,
store, and release DA, formed from exogenous levodopa, but due
to the lack of any autoregulatory feedback control, the DA released
from serotonin terminals generally show excessive swings in the
patients in response to repetitive, intermittent levodopa treatment
(44). Such dysregulated release of levodopa-derived DA is likely
to be the main trigger of dyskinesia in levodopa-primed animals
(44), and may also play a role in PD patients undergoing long-term
levodopa therapy (45, 46). Using animal models, Rylander et al.
(47) provided the first evidence that levodopa treatment induces
sprouting of serotonin axon terminals, with an increased incidence
of synaptic contacts and a larger activity-dependent potentiation
of DA release in the DA-denervated striatum. This latter finding
is of great interest since our reported morphological abnormali-
ties in patients with LIDs (33, 36) highlighted the role of the IFC,
a region strongly innervated and regulated by the serotonergic
system (48, 49).
Interestingly, similar evidence, highlighting the presence of
neural abnormalities in the IFC driven by chronic DA therapy, has
also been provided in the psychiatric realm. In particular, chronic
psychotropic treatment might cause either adaptive changes in DA
receptors (increase in the number of D2 receptors and supersen-
sitivity of D1 receptors) (50) or determine structural remodeling
of the brain. Post-mortem studies investigating brains of schiz-
ophrenic patients with long duration of anti-psychotic exposure
(i.e., haloperidol) showed significant structural abnormalities (51–
54), with evidence for slight shrinkage (5%) of the brain in terms of
weight, length, and cortical volume and for enlarged (15%) ventri-
cles. Animal studies have confirmed this evidence, demonstrating
that chronic (8 weeks) exposure to both haloperidol and olanzap-
ine resulted in significant decreases in whole-brain volume (6–8%)
driven mainly by a decrease in frontal cerebral cortex volume
(8–12%) (55). Finally, a recent in vivo neuroimaging study inves-
tigating the neuroanatomical differences between schizophrenic
patients with TDs with respect to patients without TDs (closely
matched for age at onset of illness, duration of illness, or anti-
psychotic chlorpromazine equivalent dose) demonstrated, for the
first time, the presence of volumetric abnormalities in the same
prefrontal region described in patients with LIDs: the IFC. The
merit of this work (56) was to provide evidence on the presence of
maladaptive neural rearrangements in the IFC driven by chronic
psychotropic treatment.
CONCLUSION
Although all these findings are pieces of a very difficult puzzle
to assemble, what clearly emerged is that all these disorders have
been associated with altered DA turnover induced by long-term
drug treatment that might ultimately induce maladaptive synaptic
plasticity. We believe that further advances in the understanding of
the maladaptive mechanisms of synaptic plasticity in other hyper-
kinetic movement disorders (Tourette syndrome, dystonia, and
Huntington’s disease) will lead in the next few years to defining the
exact biological impact of chronic DA therapy on the neurological
and psychiatric brain, which might ultimately stimulate develop-
ment for new treatments. For instance, in a recent neuroimaging
study, Ganos et al. (57) described the presence of gray matter
abnormalities of the IFC in patients affected by Tics in Gilles de la
Tourette syndrome. So far, evidence emerging from recent molecu-
lar and neuroimaging studies would seem to suggest an intriguing
hypothesis that some important hyperkinetic movement disor-
ders might share similar pathophysiological mechanisms (7). In
particular, part of these shared mechanisms would seem to be
localized outside the classical motor pathway (cerebellum-striato-
thalamic-motor network), involving a critical region (IFC) taking
part in the hyperdirect pathway, a neural circuit playing a critical
role in motor control (58), which might become a new potential
therapeutic target for future studies (59).
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